RecruitMe Clinical Trial
A Phase 2, multicenter, open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS)
Eribulin Mesylate in Pediatric Subjects with Rhabdomyosarcoma (RMS), non-Rhabdomyosarcoma Soft Tissue Sarcoma(NRSTS) and Ewing Sarcoma(EWS)
| Sponsor: | Eisai |
| Enrolling: | Male and Female Patients |
| Age Range: | Between 1 and 18 years old |
| IRB Number: | AAAS0709 |
| U.S. Government ID: | NCT03441360 |
| Contact: | Rebecca Zylber, CPNP: 212-305-7212 / rjv2107@cumc.columbia.edu |
Additional Study Information:
The main purpose of this study is to see if eribulin might work and might be used in the treatment of pediatric subjects with rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS) that has either come back or has not responded to the standard therapy. Eribulin will be administered as an intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle.
